Trial Profile
A Phase I Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1001 (L-Grb-2 Antisense Oligonucleotide) in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Philadelphia Chromosome Positive Chronic Myelogenous Leukemia, or Acute Lymphoblastic Leukemia, and Myelodysplastic Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Prexigebersen (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Bio-Path Holdings
- 26 May 2020 Status changed from active, no longer recruiting to completed.
- 29 Mar 2018 According to a Bio-Path Holdings media release, the article of this trial was selected for commentary by Xavier Thomas and Etienne Paubelle
- 29 Mar 2018 According to a Bio-Path Holdings media release, data from this trial was published in the online edition of The Lancet Haematology 2018.